Shanzhi Wang, Ph.D.

  1. Home
  2. Academics
  3. Our Faculty
  4. Shanzhi Wang, Ph.D.
Associate Professor
Pharmaceutical Sciences
College of Pharmacy and Health Sciences
Ph.D., Biochemistry, Texas A&M University B.S., Clinical Medicine, Jilin University, China

Dr. Shanzhi Wang joined St. John’s University in the Fall of 2022 as an Associate Professor in the Department of Pharmaceutical Sciences within the College of Pharmacy and Health Sciences. Prior to Joining St. John’s, Dr. Wang served as Assistant Professor at University of Arkansas at Little Rock (2016–22). Dr. Wang earned a Ph.D. in Biochemistry from Texas A&M University.

Areas of Expertise

His research focuses on drug development using chemistry and biology tools. The Wang group studies enzyme chemical mechanisms for small molecule inhibitor developments. In addition, the Wang group is working closely with experimental biology and bioinformatics labs to create new therapeutic proteins (not antibodies) through protein engineering.

  1. Wang, S., Lee, K., Gray, S., Zhang, Y., Tang, C., Morrish, R.B., Tosti, E., van Oers, J., Amin, M.R., Cohen, P.E., MacCarthy, T., Roa, S.*, Scharff, M.D.*, Edelmann, W.*, and Chahwan, R.* (2022) Role of EXO1 nuclease activity in genome maintenance, the immune response and tumor suppression in Exo1D173A mice. Nucleic Acids Res. 50: 8093-8106.
     
  2. Yang, F.#, Bettadapura, S.N.#, Smeltzer, M.S., Zhu, H. *, and Wang, S.* (2022) Pyroptosis and pyroptosis-inducing cancer drugs. Acta Pharmacol Sin. doi: 10.1038/s41401-022-00887-6. Online ahead of print.
     
  3. Yang, F., Darsey J.D., Ghosh A., Li H.Y., Yang, M.Q.*, and Wang, S.* (2022) Artificial Intelligence and Cancer Drug Development. Recent Pat Anticancer Drug Discov. 17: 2-8.
     
  4. Burdette, B.E.#, Esparza, A.#, Zhu, H.*, and Wang, S.* (2021) GsdmD in pyroptosis. Acta Pharmaceutica Sinica B, 11: 2768-2782.
     
  5. Yang, F., Gilreath, C., Wang, S.*, and Jiang, Q.* Bowman-Birk Inhibitors from Plants for Inhibiting Eukaryotic Cells E.S. Food Agrofor., 4: 3-4.
     
  6. Wang, D., Behura, S., Karim, F., Kazi, A., Wangila, G.*, Wang, S.* Nanoscience and Nanotechnology for Food and Agroforestry. E.S. Food Agrofor., 3: 1-3.
     
  7. Zubair, M., Wang, S.*, andAli, N.*(2021)Advanced Approaches to Breast Cancer Classification and Diagnosis. Frontiers in Pharmacology 11:632079.
     
  8. Gilreath, C., Borrma, M., Qin, Z., Hudson, M.K.*, and Wang, S.* (2021) The Hypoxic Microenvironment of Breast Cancer Cells Promotes Resistance in Radiation Therapy. Frontiers in Oncology 10: 629422.
     
  9. Barrett, L., Dai, L., Wang, S., Qin, Z.* (2021) Kaposi's sarcoma-associated herpesvirus and extracellular vesicles. J Med Virol. 93:3294-3299
     
  10. Patel, L.#, Shukla, T.#, Huang, X., Ussery, D.W., and Wang, S* (2020) Machine Learning Methods in Drug Discovery. Molecules. 25:5527.
     
  11. Yan, Z., and Wang, S.* (2020) Proteoglycans as Therapeutic Targets in Brain Cancer. Frontiers in Oncology 10: 1358.
     
  12. Geng, B.,Choi, K.H., Wang, S., Chen, P., Pan, X., Dong, N., Ko, J.K., and Zhu, H.* (2020) A simple, quick and efficient CRISPR/Cas 9 genome editing method for human induced pluripotent stem cells. Acta Pharmacologica Sinica 41: 1427-1432.
     
  13. Zhang, D.#, Burdette, B.E.#, Wang, Z., Karn, K., Li, H.Y.*, Schramm, V.L.*, Tyler, P.C., Evans, G.B., Wang, S.* (2020) Transition state analogues enhanced by fragment-based structural analysis: bacterial methylthioadenosine nucleosidases, Biochemistry 59:831-835.
     
  14. Hu, J., Duan, Z., Yu, G. and Wang, S. * (2019) Bcl-2 inhibitors as sensitizing agents for cancer chemotherapy, Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy, 2019: 151-168.
     
  15. Wang, S., Chahwan, R., Wei, L., and Scharff, M.D.* (2016) Error prone mismatch and base excision DNA repair in somatic hypermutation, Encyclopedia of Immunology 2: 126-133.
     
  16. Wang S., Cameron S.A., Clinch K.*, Evans G.B., Wu Z., Schramm V.L.*, and Tyler P.C.* (2015) New antibiotic candidates against Helicobacter pylori, Journal of the American Chemical Society 137:14275-80.
     
  17. Wei, L., Chahwan, R., Wang, S., Wang, X., Phuong, P., Goodman, M., Bergman, A., Scharff, M.D.*, and MacCarthy, T.* (2015) Overlapping hotspots in CDRs are critical sites for V region diversification, Proceedings of the National Academy of Sciences 112:E728-37.
     
  18. Wang, S., Thomas, K., and Schramm, V.L.* (2014) Catalytic site cooperativity in dimeric methylthioadenosine nucleosidase Biochemistry 53, 1527-1535.
     
  19. Wang, S., Haapalainen, A. M., Yan, F., Du, Q., Tyler, P. C., Evans, G. B., Rinaldo-Matthis, A., Brown, R. L., Norris, G. E., Almo, S. C., and Schramm, V. L.* (2012) A picomolar transition state analogue inhibitor of MTAN as a specific antibiotic for Helicobacter pylori, Biochemistry 51, 6892-6894.
     
  20. Wang, S., Lim, J., Thomas, K., Yan, F., Angeletti, R.H., and Schramm, V.L.* (2012) A complex of methylthioadenosine/S-adenosylhomocysteine nucleosidase, transition state analogue, and nucleophilic water identified by mass spectrometry, Journal of the American Chemical Society 134, 1468-1470.
     
  21. Wang, S., Lasagna, M., Daubner, S.C., Reinhart, G.D., and Fitzpatrick, P.F.* (2011) Fluorescence spectroscopy as a probe of the effect of phosphorylation at serine 40 of tyrosine hydroxylase on the conformation of its regulatory domain, Biochemistry 50, 2364-2370.
     
  22. Daubner, S.C.*, Le, T., and Wang, S. (2011) Tyrosine hydroxylase and regulation of dopamine synthesis, Archives of biochemistry and biophysics 508, 1-12.
     
  23. Wang, S., Sura, G.R., Dangott, L.J., and Fitzpatrick, P.F.* (2009) Identification by hydrogen/deuterium exchange of structural changes in tyrosine hydroxylase associated with regulation, Biochemistry 48, 4972-4979.